

Cambridge University Press

978-1-107-68159-0 - Stahl's Self-Assessment Examination in Psychiatry: Multiple Choice Questions for Clinicians

Stephen M. Stahl

Index

[More information](#)

INDEX

A

- absorption problems, 63–4
- acetylcholine
 - and extrapyramidal side effects, 59–60
 - memory pathways, 257–8
- action potentials, ion flow, 29–30
- aggression
 - in dementia, citalopram for, 267–8
 - link to orbital frontal cortex, 41–2
- agitation, citalopram for, 267–8
- agomelatine, 229–30
- agoraphobia, 175–6
- alcoholism
 - naltrexone for, 289–91
 - reduced-risk drinking, 297–8
- allodynia, symptoms of, 185–6
- Alzheimer's disease (AD)
 - and renal failure,
 - contraindications, 271–2
 - beta amyloid accumulation in brain, 273–4
 - biomarkers for early detection, 275–6
 - diagnosis of, 255–6
 - L-methyl-folate efficacy, 265–6
 - medications for smokers, 261–2
 - order of symptoms, 259–60
- amantadine, for tardive dyskinesia, 75–6
- amitriptyline, for fibromyalgia, 199–200
- amygdala
 - and dopamine release, 277–8, 283–4
 - and re-experiencing of PTSD symptoms, 159–60
 - and suicidality, 81–2
- anterior cingulate cortex, 232
 - and selective attention, 239–40
- antioxidant levels, increase in, 121–2
- antipsychotics
 - bypassing absorption problems, 63–4
 - Del allele carriers' response to, 117–18
 - least likely to cause sedation, 67–8
 - therapeutic and side-effect profile, 47–8
 - weight gain and metabolic issues, 65–6, 77–8
- anxiety
 - and breathing difficulty, 151–2
 - genes responsible for, 165–6
- apathy
 - brain regions involved in, 133–4
 - SSRI-induced indifference, 113–14
- apoptosis, 13–14, 121–2
- aripiprazole, 67–8, 129–30, 139–40
- asenapine, 63–4, 77–8
- atomoxetine, 95–6, 237–8
 - dose adjustment for liver-damaged patient, 249–50
 - interaction with paroxetine, 247–8
- attention deficit hyperactivity disorder (ADHD)
 - adult symptoms, identification of, 245–6
 - and rapid discontinuation of clonidine, 241–2
 - and substance use, 243–4
- atomoxetine and abuse potential, 237–8

Cambridge University Press

978-1-107-68159-0 - Stahl's Self-Assessment Examination in Psychiatry: Multiple Choice Questions for Clinicians

Stephen M. Stahl

Index

[More information](#)

STAHL'S SELF-ASSESSMENT EXAMINATION IN PSYCHIATRY

attention deficit hyperactivity disorder (ADHD) (cont.)
 atomoxetine-paroxetine interaction, 247–8
 cortical maturation, children, 233–4
 lisdexamfetamine for adults, 253–4
 pulsatile stimulation leading to abuse, 235–6
 selective attention test, 239–40
 stimulant treatment for children, 251–2
 sustained attention, brain region involved in, 231–2
 axoaxonal connections, cell pairing, 9–10
 axonal transport, 5–6

B

basal forebrain, role in memory, 257–8
 benzotropine, 75–6
 beta adrenergic blockers, preemptive treatment for PTSD, 177–8
 beta-amyloid protein, accumulation in AD brain, 273–4
 biomarkers for early detection of AD, 275–6
 bipolar disorder
 brain area involved in symptoms, 133–4
 clinical course of, 119–20
 glutamate release, drugs reducing, 131–2
 medication during pregnancy, 125–6
 monoamine projections
 accounting for mania, 123–4
 mood stabilizer mechanism, 121–2
 rapid-cycling, medication for, 129–30
 recommended pharmacologic treatment, 127–8
 brain-derived neurotrophic factor (BDNF), 109–10
 reduced in chronic stress conditions, 153–4

breast secretions, explanation for, 49–50
 breathing difficulty, parabrachial nucleus, 151–2
 buprenorphine, opioid addiction, 299–301
 bupropion
 and modafinil, depression treatment, 103–4
 contraindicated with phenelzine, 287–8
 buspirone, 171–2

C

caffeine consumption, night shift workers, 227–8
 cannabinoid CB1 receptor antagonist, 295–6
 catechol-O-methyltransferase (COMT) gene, 102
 and depression, 117–18
 and susceptibility to worry and anxiety disorders, 165–6
 CBT (cognitive-behavioral therapy), for PTSD, 167–8
 chandelier neurons, axoaxonal connections, 9–10
 chemical burn, afferent neuron response, 189–90
 cholinesterase inhibitors, Alzheimer's disease, 261–2
 chronic stress, effect on BDNF production and hippocampal volume, 153–4
 circadian rhythm
 agomelatine, role in modulating, 229–30
 effect of night shift work, 225–6
 phase-advanced, treatment for, 217–18
 role of melatonin, 31–2
 classic synaptic neurotransmission, 19–20
 clomipramine overdose, effects of, 95–6
 clonazepam, dose for panic disorder, 169–70

STAHL'S SELF-ASSESSMENT EXAMINATION IN PSYCHIATRY

- clonidine, effects of rapid
 discontinuation of, 241–2
- clozapine, side effects, 139–40
- codeine, effects of paroxetine on
 efficacy of, 155–6
- cognitive dysfunction
 depression-executive
 dysfunction, 269–70
 effect of milnacipran, 197–8
 in bipolar disorder, 119–20
 schizophrenia, 39–40
- cognitive flexibility, role of
 dorsolateral prefrontal cortex,
 279–80
- cognitive performance in
 narcolepsy, 223–5
- cognitive restructuring therapy,
 179–80
- cognitive-behavioral therapy
 (CBT), for PTSD, 167–8
- COMT gene, 102, 117–18, 165–6
- conventional antipsychotics, profile
 of, 47–8
- corticotropin releasing hormone
 (CRH) gene expression,
 173–4
- cross-titration, 69–70, 73–4
- CYP450 1A2 enzyme
 inhibition by fluvoxamine,
 97–8
 smoking inducing, 137–8
- CYP450 2D6 enzyme inhibition,
 paroxetine, 155–6
- CYP450 enzymes, mirtazapine
 interaction, 99–100
- D**
-
- D2 receptors, upregulation, 27–8
- dementia
 citalopram for agitation and
 aggression, 267–8
 depression-executive
 dysfunction, 269–70
- depolarization, NMDA receptors,
 35–6
- depression-executive dysfunction,
 269–70
- desvenlafaxine for VMS in
 depression, 87–8
- diabetic peripheral neuropathy,
 195–6
- donepezil, 75–6, 262, 271–2
- dopamine 2 receptor gene
 (DRD2), 117–18
- dopamine 2 receptor upregulation
 impetus for, 27–8
 tardive dyskinesia, 45–6
- dopamine deficiency
 causing daytime sleepiness,
 207–8
 in prefrontal cortex, 117–18
- dopamine partial agonists (DPAs),
 switching to, 73–4
- dopamine release
 due to “natural highs”, 277–8
 from amygdala to VTA, 283–4
- dorsolateral prefrontal cortex
 and sustained attention, 231–2
 role in cognitive flexibility,
 279–80
- doxepin, effects of higher doses,
 219–20
- drug “hangover” effect, 211–12
- drug tolerance, 213–14
- duloxetine, and chronic hepatitis,
 avoidance of, 203–4
- E**
-
- electroconvulsive therapy (ECT),
 105–6
- epigenetics, 33–4
- escitalopram, 103–4
- eszopiclone
 for sleep cycle problems,
 209–10
 plus sertraline for GAD, 215–16
- extrapyramidal side effects (EPS),
 adjunct medication, 59–60
- F**
-
- fetus, neurogenesis stage, 11–12
- fibromyalgia, 183–4, 201–2
- milnacipran benefits, 197–8

STAHL'S SELF-ASSESSMENT EXAMINATION IN PSYCHIATRY

fibromyalgia (cont.)
 pregabalin, molecular action,
 193–4
 second-line monotherapy,
 199–200
 fluoxetine, 103–4, 107–8

G

G protein coupling, 25–6
 GABA-A receptors
 and sleep cycle disturbances,
 209–10
 involved in panic attacks, 163–4
 gabapentin, 129–30
 galantamine, 261–2, 271–2
 generalized anxiety disorder
 (GAD), 149–50
 buspirone, mechanism of, 171–2
 effect on BDNF and
 hippocampal volume,
 153–4
 eszopiclone plus sertraline,
 215–16
 genetics
 COMT and MTHFR genes and
 depression, 117–18
 COMT Met genotype and
 anxiety, 165–6
 CRH gene and early-life stress,
 173–4
 Del allele carriers, 115–16
 glutamate release
 drugs reducing, 131–2
 from pyramidal neurons, 91–2
 glutamate, activating NMDA
 receptors, 35–6
 glutamate-serotonin interactions,
 111–12
 glycine, NMDA receptor
 activation, 35–6

H

hallucinations, 25–6, 61–2
 haloperidol, 59–60
 hepatitis, duloxetine
 contraindicated, 203–4

hippocampus
 role in PTSD, 159–60
 volume decreased by chronic
 stress, 153–4
 histamine 1 (H1) receptor blockade
 and weight gain, 89–90, 135–6
 homeostatic (sleep) drive,
 unaffected by night shift work,
 225–6
 homocysteine levels and AD,
 265–6
 HPA axis functioning, changes
 caused by severe early-life
 stress, 173–4
 hyperalgesia, 185–6
 hypertension
 and rapid discontinuation of
 clonidine, 241–2
 tranylcypromine-tyramine
 reaction, 93–4
 hypothalamus
 link to apathy, weight gain and
 insomnia, 133–4
 link to sleep problems, 201–2

I

ibuprofen
 and lithium toxicity, 141–2
 inefficacy for fibromyalgia,
 199–200
 iloperidone
 for prevention of orthostatic
 hypotension, 55–6
 weight and metabolic profiles,
 77–8
 indifference, SSRI-induced, 113–14
 infection, side effects of, 141–2
 insomnia
 and anxiety, treatment for,
 215–16
 brain region associated with,
 201–2
 trazodone for, 213–14
 ion channels, transmembrane,
 23–4
 ion flow during action potential,
 29–30

STAHL'S SELF-ASSESSMENT EXAMINATION IN PSYCHIATRY

K

kinase phosphorylation of CREB,
 25–6

L

lamotrigine, 129–30, 137–8
 and quetiapine for bipolar
 disorder, 127–8
 reducing glutamate release, 131–2
 ligand-gated ion channels, 23–4
 NMDA receptors, activation of,
 35–6
 lisdexamfetamine, adult ADHD,
 253–4
 lithium, 143–4
 contraindicated in pregnancy,
 125–6
 increasing antioxidant levels,
 121–2
 toxic when combined with
 ibuprofen, 141–2
 liver damage
 atomoxetine dose adjustment,
 249–50
 duloxetine contraindicated,
 203–4
 L-methylfolate (MTHF)
 boosting efficacy of
 antidepressants, 101–2
 efficacy in Alzheimer's disease,
 265–6
 lurasidone, 77–8

M

mania symptoms, monoamine
 projections resulting in,
 123–4
 marijuana abuse, rimonabant,
 295–6
 medication absorption problems,
 63–4
 melatonin, 31–2, 217–18, 229–30
 memantine, 271–2
 properties useful in treating AD,
 263–4

memory

brain regions involved in, 257–8
 re-experiencing of, 159–60
 menopause and depression, 87–8
 meperidine, contraindicated with
 MAOIs, 205–6
 mesolimbic pathway, dopamine
 release, 277–8
 migraines in children, topiramate,
 143–6
 milnacipran, 197–8
 mirtazapine
 CYP450 enzyme interaction,
 99–100
 weight gain side effect, 89–90
 mitochondrial dysfunction, 121–2
 modafinil + bupropion, depression
 treatment, 103–4
 monoamine oxidase inhibitors
 (MAOIs)
 opioids contraindicated, 205–6
 reaction with tyramine in food,
 93–4
 monoamine projections and mania
 symptoms, 123–4
 monoamine synthesis,
 L-methylfolate, 101–2
 MTHFR gene, role in
 depression, 117–18
 mu-opioid receptors, naltrexone
 blocking, 289–91, 292
 muscarinic 1 antagonism, EPS
 relief, 59–60

N

naltrexone for alcoholism, 291–2
 mechanism of action, 289–91
 narcolepsy, role of stimulants, 223–5
 natural highs, dopamine release,
 277–8
 necrosis, 13–14
 nerve growth factor (NGF), 21–2
 neurogenesis, fetal, 11–12
 neurons, signal transduction, 1–2
 neuropathic pain, 185–6
 and chronic hepatitis, avoidance
 of duloxetine, 203–4

Cambridge University Press

978-1-107-68159-0 - Stahl's Self-Assessment Examination in Psychiatry: Multiple Choice Questions for Clinicians

Stephen M. Stahl

Index

[More information](#)

STAHL'S SELF-ASSESSMENT EXAMINATION IN PSYCHIATRY

neuropathic pain (cont.)
 milnacipran for, 197–8

neuroscience
 action potentials, 29–30
 nerve growth factor (NGF),
 21–2
 neurogenesis, fetal, 11–12
 neurotransmission, 19–20, 21–2
 protein synthesis, site of, 3–4
 receptor speed, 5–6
 signal transduction, site of, 1–2
 synapses, scaffolding process,
 15–16

neurotransmission, 19–20, 21–2,
 27–8
 agoraphobia, 175–6
 circadian rhythm, 31–2
 dementia, 257–8
 pain relief, 193–4

nicotine cravings, recovery from,
 285–6

night shift workers, caffeine
 consumption, 227–8

nitric oxide synthetase (NOS)
 inhibition and sexual
 dysfunction, 85–6

N-methyl-*D*-aspartate (NMDA)
 memantine and treatment of AD,
 263–4
 receptor activation, 35–6

nociceptive neuronal activity,
 189–90

nonsteroidal anti-inflammatory
 drugs (NSAIDs), lithium
 toxicity, 141–2

nucleus accumbens, 41–2, 81–2,
 133–4, 159–60, 237–8

O

obesity
 value of rimonabant, 295–6

olanzapine, 139–40, 146
 effects of higher doses, 51–2
 effects of smoking on efficacy of,
 61–2, 137–8
 hypnotic effect of, 211–12

opiate addiction

buprenorphine treatment,
 299–301
 recovery potential, 293–5

opioids
 contraindicated with MAOIs,
 205–6
 paroxetine and codeine efficacy,
 155–6

orbital frontal cortex
 aggressive symptoms, 41–2
 and mania symptoms, 123–4
 impulsivity regulation, 232
 orthostatic hypotension, 55–6

P

pain
 allodynia, symptoms of,
 185–6
 chemical burn, neuron response,
 189–90
 continued experience of, 187–8
 diabetic peripheral neuropathy,
 195–6
 inconsistent effects of SSRIs,
 191–2

paliperidone, 63–4, 67–8

panic attacks/panic disorder,
 149–50
 clonazepam dosage, 169–70
 GABA-A receptors involved in,
 163–4
 neurotransmitters implicated in,
 175–6

parabrachial nucleus, respiration
 regulation, 151–2

paroxetine
 and atomoxetine interaction,
 247–8
 and decreased effectiveness of
 codeine, 155–6
 for PTSD, 157–8
 pharmacokinetics of, 85–6

periodic limb movement disorder
 (PLMD), 221–2

perphenazine, 49–50, 67–8

phase-advanced circadian rhythms,
 treatment for, 217–18

Cambridge University Press

978-1-107-68159-0 - Stahl's Self-Assessment Examination in Psychiatry: Multiple Choice Questions for Clinicians

Stephen M. Stahl

Index

[More information](#)

STAHL'S SELF-ASSESSMENT EXAMINATION IN PSYCHIATRY

- phasic/pulsatile vs. tonic/sustained stimulation, 235–6
- polysomnograph test for PLMD/PLMS, 221–2
- posttraumatic stress disorder (PTSD)
- and comorbid SUD, safety therapy, 181–2
 - anxiolytic effects of sertraline, 161–2
 - brain regions involved in, 159–60
 - cognitive restructuring therapy, 179–80
 - fear extinction therapy, 167–8
 - first-line treatment, 157–8
 - preemptive treatment for, 177–8
 - stress diathesis hypothesis, 17–18
- prefrontal cortex
- and memory, 257–8
 - atomoxetine inhibiting NET, 237–8
 - decreased dopamine, 117–18
 - overactivity, treatment for, 91–2
 - pyramidal cells, 7–8
- pregabalin, 193–4, 197–8, 203–4
- pregnancy
- bipolar disorder medication, 125–6
 - fetal neurogenesis, 11–12
- prolactin release, explanation for, 49–50
- propranolol preempting development of PTSD, 177–8
- protein synthesis, site of, 3–4
- proteins, direction and speed of discarded, 5–6
- psychosis
- brain region linked to aggression, 41–2
 - detecting negative symptoms, 37–8
- pyramidal cells/neurons, 7–8
- axoaxonal connections, 9–10
 - glutamate release, 91–2
- Q**
- quetiapine
- and lamotrigine for bipolar disorder, 127–8
 - receptor blockade causing weight gain, 135–6
 - relieving breast secretions, 49–50
- R**
- rapid-cycling bipolar disorder, valproate, 129–30
- reduced-risk drinking, 297–8
- relapse, depression, 79–80
- reserpine, 75–6
- respiration difficulties, anxiety, 151–2
- retrograde neurotransmission, 21–2
- reward brain circuits, 283–4
- rimonabant, 295–6
- risperidone, 63–4, 65–6
- cross-titration as switching method, 69–70
 - target therapeutic dose for adolescent, 71–2
- rivastigmine, 261–2, 271–2
- rough endoplasmic reticulum, protein synthesis, 3–4
- S**
- safety therapy, comorbid SUD and PTSD, 181–2
- scaffolding, synapses, 15–16
- schizophrenia
- and extrapyramidal side effects (EPS), 59–60
 - cognitive functioning in, 39–40
 - development of tardive dyskinesia, 45–6
 - early neurogenesis regulated by DISC-1 protein, 43–4
 - effects of higher doses of olanzapine, 51–2
 - hallucinogenic effect of smoking, 61–2
 - iloperidone for prevention of orthostatic hypotension, 55–6

STAHL'S SELF-ASSESSMENT EXAMINATION IN PSYCHIATRY

- schizophrenia (cont.)
 medication absorption problems,
 63–4
 medication least likely to cause
 sedation, 67–8
 serotonin 2A antagonism, 53–4
 target therapeutic dose for
 adolescent, 71–2
 sedation, lowest risk medication,
 67–8
 selective attention, test of, 239–40
 selective serotonin reuptake
 inhibitors (SSRIs)
 benefits of adding to hypnotics,
 215–16
 inconsistent effects on pain,
 191–2
 indifference induced by, 113–14
 meperidine contraindicated with
 MAOIs, 205–6
 serotonin 1A receptors, effect of
 buspirone, 171–2
 serotonin 2A antagonism, 53–4,
 135–6
 serotonin 2C antagonism
 and agomelatine binding,
 229–30
 and weight gain, 57–8, 89–90,
 135–6
 serotonin 5HT7 receptors, function
 of, 111–12
 serotonin antagonist/reuptake
 inhibitors (SARIs), 91–2
 serotonin dopamine antagonists
 (SDAs), switching from,
 73–4
 serotonin transporter (SERT)
 gene, 165–6
 sertraline
 anxiolytic effects of, 161–2
 plus eszopiclone for GAD,
 215–16
 sexual dysfunction
 due to NOS inhibition, 85–6
 treatment combination for,
 103–4
 signal transduction site, neurons,
 1–2
 sleep problems
 daytime sleepiness and dopamine
 deficiency, 207–8
 eszopiclone treatment, 209–10
 hypnotic effect of olanzapine,
 211–12
 hypothalamus linked to, 133–4,
 201–2
 narcolepsy, cognitive
 performance restored with
 stimulants, 223–5
 sertraline plus eszopiclone for
 GAD, 215–16
 sleep/wake switch, treatment for
 resetting, 217–18
 trazodone for inducing sleep,
 213–14
 smoking
 cessation, pharmacologic
 therapy, 287–8
 recovery from nicotine
 addiction, 285–6
 reducing olanzapine efficacy,
 137–8
 therapeutic value of rimobant,
 295–6
 social anxiety disorder, 163–4
 stimulants
 for ADHD in children, 251–2
 phasic/pulsatile delivery leading
 to abuse, 235–6
 restoring cognitive performance
 in narcolepsy, 223–5
 stress
 and changes in HPA axis
 functioning, 173–4
 and hippocampal volume
 decrease, 153–4
 stress diathesis hypothesis, PTSD,
 17–18
 Stroop task, selective attention test,
 239–40
 substance abuse and comorbid
 ADHD, 243–4
 preferred treatment order,
 281–2
 substance abuse and comorbid
 PTSD, therapy for, 181–2

Cambridge University Press

978-1-107-68159-0 - Stahl's Self-Assessment Examination in Psychiatry: Multiple Choice Questions for Clinicians

Stephen M. Stahl

Index

[More information](#)

STAHL'S SELF-ASSESSMENT EXAMINATION IN PSYCHIATRY

- suicidality, role of amygdala, 81–2
- suprachiasmatic nucleus (SCN), 31–2
- treatment for resetting, 217–18
- sustained attention, brain region involved in, 231–2
- synapses, scaffolding process, 15–16
- T**
- tardive dyskinesia, 45–6, 75–6
- theophylline, inhibition by fluvoxamine, 97–8
- titration schedules
- iloperidone, 55–6
- varenicline, 287–8
- when adding lamotrigine to valproate, 147–8
- ziprasidone, 145–6
- topiramate, for migraine, dose range for children, 143–4
- tranylcypromine, tyramine reaction, 93–4
- trazodone, 103–4, 213–14
- tyramine in food, reaction with MAOIs, 93–4
- U**
- unipolar depression
- antipsychotic drug response, Del allele carriers, 115–16
- brain-derived neurotrophic factor (BDNF), 109–10
- clomipramine overdose, effects of, 95–6
- COMT and MTHFR genes, 117–18
- desvenlafaxine for VMS, 87–8
- electroconvulsive therapy (ECT) for, 105–6
- fluoxetine for, 107–8
- fluvoxamine and theophylline, 97–8
- L-methylfolate, value of, 101–2
- mirtazapine, CYP450 enzyme interaction, 99–100
- relapse, symptom renewal, 79–80
- SARIs moderating glutamate release, 91–2
- sexual dysfunction as medication side effect, 85–6, 103–4
- SSRIs, indifference induced by, 113–14
- suicidality, role of amygdala, 81–2
- symptoms, cause of, 83–4
- tranylcypromine, tyramine reaction, 93–4
- weight gain, mirtazapine side effect, 89–90
- V**
- valproate, 121–2
- contraindicated in pregnancy, 125–6
- for rapid-cycling bipolar disorder, 129–30
- reduction of glutamate release, 131–2
- varenicline, smoking cessation, 287–8
- vasomotor symptoms (VMSs), desvenlafaxine, 87–8
- venlafaxine, 95–6
- ventral tegmental area (VTA), dopamine release from amygdala, 283–4
- ventromedial prefrontal cortex, link to mania symptoms, 123–4
- voltage-sensitive calcium channels (VSCCs)
- and excessive stimulation of glutamate release, 131–2
- and pain alleviation, 193–4
- voltage-sensitive sodium channels (VSSCs)
- drugs blocking, 96, 131–2
- pain transduction and conduction, 187–8

Cambridge University Press
 978-1-107-68159-0 - Stahl's Self-Assessment Examination in Psychiatry: Multiple
 Choice Questions for Clinicians
 Stephen M. Stahl
 Index
[More information](#)

STAHL'S SELF-ASSESSMENT EXAMINATION IN PSYCHIATRY

W

weight gain
 and antipsychotics, 65–6,
 77–8
 and inefficient information
 processing in
 hypothalamus, 133–4
 due to antagonism of serotonin
 2C receptors, 57–8

mirtazapine causing,
 89–90
 quetiapine inducing receptor
 blockade, 135–6
 topiramate dosage for children,
 143–6

Z

ziprasidone, 65–6, 139–40, 145–6